Induction of mucosal tolerance in SLE: A sniff or a sip away from ameliorating lupus?

Clinical Immunology

Volumn 130, Issue 2, 2009, Pages 111-122

  Wu, Henry Yim ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Autoimmune diseases; Mucosal tolerance; Regulatory T cells; Systemic lupus erythematosus

Indexed keywords

BELIMUMAB; COLLAGEN TYPE 2; COLLORAL; CYCLOPHOSPHAMIDE; CYTOKINE; EPRATUZUMAB; GAMMA INTERFERON; GLATIRAMER; INSULIN; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 2; METHYLPREDNISOLONE; MYELIN; OVALBUMIN; PLACEBO; RETINA S ANTIGEN; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AUTOIMMUNITY; BEHCET DISEASE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION; INSULIN TREATMENT; INTERMEDIATE UVEITIS; MUCOSAL IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL;

CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MUCOUS MEMBRANE; T-LYMPHOCYTES, REGULATORY;

EID: 58049083261     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.08.028     Document Type: Short Survey

References (159)

1. Amoura Z., Piette J.C., Bach J.F., and Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum. 42 (1999) 833-843
2. Theofilopoulos A.N., and Dixon F.J. Etiopathogenesis of murine SLE. Immunol. Rev. 55 (1981) 179-216
3. Strobel S., and Mowat A.M. Immune responses to dietary antigens: oral tolerance. Immunol. Today 19 (1998) 173-181
4. Ngan J., and Kind L.S. Suppressor T cells for IgE and IgG in Peyer's patches of mice made tolerant by the oral administration of ovalbumin. J. Immunol. 120 (1978) 861-865
5. Vaz N.M., Maia L.C., Hanson D.G., and Lynch J.M. Inhibition of homocytotropic antibody responses in adult inbred mice by previous feeding of the specific antigen. J. Allergy Clin. Immunol. 60 (1977) 110-115
6. Miller S.D., and Hanson D.G. Inhibition of specific immune responses by feeding protein antigens. IV. Evidence for tolerance and specific active suppression of cell-mediated immune responses to ovalbumin. J. Immunol. 123 (1979) 2344-2350
7. Mowat A.M., Strobel S., Drummond H.E., and Ferguson A. Immunological responses to fed protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide. Immunology 45 (1982) 105-113
8. Hanson D.G., et al. Inhibition of specific immune responses by feeding protein antigens. Int. Arch. Allergy Appl. Immunol. 55 (1977) 526-532
9. Richman L.K., Chiller J.M., Brown W.R., Hanson D.G., and Vaz N.M. Enterically induced immunologic tolerance. I. Induction of suppressor T lymphoyctes by intragastric administration of soluble proteins. J. Immunol. 121 (1978) 2429-2434
10. Titus R.G., and Chiller J.M. Orally induced tolerance. Definition at the cellular level. Int. Arch. Allergy Appl. Immunol. 65 (1981) 323-338
11. Hanson D.G., and Miller S.D. Inhibition of specific immune responses by feeding protein antigens. V. Induction of the tolerant state in the absence of specific suppressor T cells. J. Immunol. 128 (1982) 2378-2381
12. Higgins P.J., and Weiner H.L. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 140 (1988) 440-445
13. Lider O., Santos L.M., Lee C.S., Higgins P.J., and Weiner H.L. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+T lymphocytes. J. Immunol. 142 (1989) 748-752
14. Fishman-Lobell J., Friedman A., and Weiner H.L. Different kinetic patterns of cytokine gene expression in vivo in orally tolerant mice. Eur. J. Immunol. 24 (1994) 2720-2724
15. Weiner H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today 18 (1997) 335-343
16. Weiner H.L., Gonnella P.A., Slavin A., and Maron R. Oral tolerance: cytokine milieu in the gut and modulation of tolerance by cytokines. Res. Immunol. 148 (1997) 528-533
17. Faria A.M., and Weiner H.L. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. 73 (1999) 153-264
18. Wu H.Y., and Weiner H.L. Oral tolerance. Immunol. Res. 28 (2003) 265-284
19. Wu H.Y., Ward F.J., and Staines N.A. Histone peptide-induced nasal tolerance: suppression of murine lupus. J. Immunol. 169 (2002) 1126-1134
20. Prakken B.J., et al. Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheum. 46 (2002) 1937-1946
21. Ochi H., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4(+)CD25(-)LAP(+) T cells. Nat. Med. 12 (2006) 627-635
22. Chen W., Jin W., and Wahl S.M. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J. Exp. Med. 188 (1998) 1849-1857
23. Nakamura K., Kitani A., and Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194 (2001) 629-644
24. Takahashi T., et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10 (1998) 1969-1980
25. Taams L.S., et al. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur. J. Immunol. 32 (2002) 1621-1630
26. Tsuji N.M. Antigen-specific CD4(+) regulatory T cells in the intestine. Inflamm. Allergy Drug Targets 5 (2006) 191-201
27. Friedman A., and Weiner H.L. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 6688-6692
28. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
29. Shevach E.M., et al. The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cells. Immunol. Rev. 212 (2006) 60-73
30. Murakami M., Sakamoto A., Bender J., Kappler J., and Marrack P. CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8832-8837
31. Annacker O., et al. CD25+CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 166 (2001) 3008-3018
32. Jiang S., and Lechler R.I. CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection. Inflamm. Allergy. Drug. Targets. 5 (2006) 239-242
33. Viehl C.T., et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann. Surg. Oncol. 13 (2006) 1252-1258
34. Strauss L., Bergmann C., and Whiteside T.L. Functional and phenotypic characteristics of CD4(+)CD25(high)Foxp3(+) Treg clones obtained from peripheral blood of patients with cancer. Int. J. Cancer 121 (2007) 2473-2483
35. Belkaid Y., Piccirillo C.A., Mendez S., Shevach E.M., and Sacks D.L. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420 (2002) 502-507
36. Aseffa A., et al. The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells. J. Immunol. 169 (2002) 3232-3241
37. Nishizuka Y., and Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 166 (1969) 753-755
38. Kojima A., Tanaka-Kojima Y., Sakakura T., and Nishizuka Y. Spontaneous development of autoimmune thyroiditis in neonatally thymectomized mice. Lab. Invest. 34 (1976) 550-557
39. Sakaguchi S., Takahashi T., and Nishizuka Y. Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer. J. Exp. Med. 156 (1982) 1565-1576
40. Sakaguchi S., Takahashi T., and Nishizuka Y. Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J. Exp. Med. 156 (1982) 1577-1586
41. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995) 1151-1164
42. Zheng S.G., Wang J., Wang P., Gray J.D., and Horwitz D.A. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J. Immunol. 178 (2007) 2018-2027
43. Abramowicz D., et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47 (1989) 606-608
44. Furtado G.C., Curotto de Lafaille M.A., Kutchukhidze N., and Lafaille J.J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196 (2002) 851-857
45. Bayer A.L., Yu A., and Malek T.R. Function of the IL-2R for thymic and peripheral CD4+CD25+Foxp3+ T regulatory cells. J. Immunol. 178 (2007) 4062-4071
46. McHugh R.S., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 (2002) 311-323
47. Morris G.P., and Kong Y.C. Interference with CD4+CD25+ T-cell-mediated tolerance to experimental autoimmune thyroiditis by glucocorticoid-induced tumor necrosis factor receptor monoclonal antibody. J. Autoimmun. 26 (2006) 24-31
48. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
49. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J. Clin. Invest. 112 (2003) 1310-1312
50. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 (2005) 345-352
51. Quintana F.J., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453 (2008) 65-71
52. Ono M., et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446 (2007) 685-689
53. Wu H.Y., and Staines N.A. A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 13 (2004) 192-200
54. Bagavant H., and Tung K.S. Failure of CD25+ T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis. J. Immunol. 175 (2005) 944-950
55. Crispin J.C., Martinez A., and Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 21 (2003) 273-276
56. Lyssuk E.Y., Torgashina A.V., Soloviev S.K., Nassonov E.L., and Bykovskaia S.N. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv. Exp. Med. Biol. 601 (2007) 113-119
57. Franz B., et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum. 56 (2007) 1910-1920
58. Valencia X., Yarboro C., Illei G., and Lipsky P.E. Deficient CD4+ CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178 (2007) 2579-2588
59. Scalapino K.J., Tang Q., Bluestone J.A., Bonyhadi M.L., and Daikh D.I. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol. 177 (2006) 1451-1459
60. Kaliyaperumal A., Mohan C., Wu W., and Datta S.K. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J. Exp. Med. 183 (1996) 2459-2469
61. Kang H.K., Michaels M.A., Berner B.R., and Datta S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J. Immunol. 174 (2005) 3247-3255
62. Kang H.K., Liu M., and Datta S.K. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J. Immunol. 178 (2007) 7849-7858
63. La Cava A., Ebling F.M., and Hahn B.H. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black × New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J. Immunol. 173 (2004) 3542-3548
64. Hahn B.H., et al. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann. N. Y. Acad. Sci. 1051 (2005) 433-441
65. Sharabi A., Zinger H., Zborowsky M., Sthoeger Z.M., and Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 8810-8815
66. Sharabi A., Azulai H., Sthoeger Z.M., and Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 121 (2007) 248-257
67. Cottrez F., and Groux H. Specialization in tolerance: innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells. Transplantation 77 (2004) S12-15
68. Powrie F., Carlino J., Leach M.W., Mauze S., and Coffman R.L. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB (low) CD4+ T-cells. J. Exp. Med. 183 (1996) 2669-2674
69. Groux H., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737-742
70. Chen W., et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 (2003) 1875-1886
71. Huber S., et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J. Immunol. 173 (2004) 6526-6531
72. Huber S., and Schramm C. TGF-beta and CD4+CD25+ regulatory T cells. Front Biosci. 11 (2006) 1014-1023
73. Weiner H.L., et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12 (1994) 809-837
74. Chen Y., Inobe J.i., and Weiner H.L. Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Cell. Immunol. 178 (1997) 62-68
75. Khoury S.J., Hancock W.W., and Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis as associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176 (1992) 1355-1364
76. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., and Weiner H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265 (1994) 1237-1240
77. Melamed D., Fishman-Lovell J., Uni Z., Weiner H.L., and Friedman A. Peripheral tolerance of Th2 lymphocytes induced by continuous feeding of ovalbumin. Int. Immunol. 8 (1996) 717-724
78. Neurath M.F., et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J. Exp. Med. 183 (1996) 2605-2616
79. Faria A.M., et al. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J. Autoimmun. 20 (2003) 135-145
80. Alpan O., Bachelder E., Isil E., Arnheiter H., and Matzinger P. 'Educated' dendritic cells act as messengers from memory to naive T helper cells. Nat. Immunol. 5 (2004) 615-622
81. Gonnella P.A., Chen Y.H., Waldner H., and Weiner H.L. Induction of oral tolerization in CD86 deficient mice: a role for CD86 and B cells in the up-regulation of TGF-beta. J. Autoimmun. 26 (2006) 73-81
82. Faria A.M., and Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13 (2006) 143-157
83. Maron R., Melican N.S., and Weiner H.L. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. J. Autoimmun 12 (1999) 251-258
84. Aroeira L.S., Cardillo F., De Albuquerque D.A., Vaz N.M., and Mengel J. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA. Scand. J. Immunol. 41 (1995) 319-323
85. Akbari O., DeKruyff R.H., and Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2 (2001) 725-731
86. Weiner H.L. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat. Immunol. 2 (2001) 671-672
87. Inobe J., et al. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 28 (1998) 2780-2790
88. Thorbecke G.J., Schwarcz R., Leu J., Huang C., and Simmons W.J. Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis Rheum. 42 (1999) 110-118
89. Zhang Z., and Michael J.G. Orally inducible immune unresponsiveness is abrogated by IFN-γ treatment. J. Immunol. 144 (1990) 4163-4165
90. Marth T., Strober W., and Kelsall B.L. High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J. Immunol. 157 (1996) 2348-2357
91. Eaton A.D., Xu D., and Garside P. Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance. Immunology 108 (2003) 196-203
92. Nelson P.A., et al. Effect of oral beta interferon on subsequent immune responsiveness. Ann. N. Y. Acad. Sci. 778 (1996) 145-155
93. Soos J.M., Mujtaba M.G., Subramaniam P.S., Streit W.J., and Johnson H.M. Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J. Neuroimmunol. 75 (1997) 43-50
94. Soos J.M., et al. Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J. Immunol. 169 (2002) 2231-2235
95. Xiao B.G., Bai X.F., Zhang G.X., and Link H. Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J. Neuroimmunol. 84 (1998) 230-237
96. Slavin A.J., Maron R., and Weiner H.L. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int. Immunol. 13 (2001) 825-833
97. Li H.L., et al. Nasal tolerance to experimental autoimmune myasthenia gravis: tolerance reversal by nasal administration of minute amounts of interferon-gamma. Clin. Immunol. Immunopathol. 87 (1998) 15-22
98. Gautam S.C., Chikkala N.F., and Battisto J.R. Oral administration of the contact sensitizer trinitrochlorobenzene: initial sensitization and subsequent appearance of a suppressor population. Cell. Immunol. 125 (1990) 437-448
99. Hoyne G.F., Callow M.G., Kuhlman J., and Thomas W.R. T-cell lymphokine response to orally administered proteins during priming and unresponsiveness. Immunology 78 (1993) 534-540
100. Hoyne G.F., and Thomas W.R. T-cell responses to orally administered antigens. Study of the kinetics of lymphokine production after single and multiple feeding. Immunology 84 (1995) 304-309
101. Mowat A.M., Steel M., Leishman A.J., and Garside P. Normal induction of oral tolerance in the absence of a functional IL-12-dependent IFN-gamma signaling pathway. J. Immunol. 163 (1999) 4728-4736
102. Mengel J., et al. Anti-gamma delta T cell antibody blocks the induction and maintenance of oral tolerance to ovalbumin in mice. Immunol. Lett. 48 (1995) 97-102
103. Ke Y., Pearce K., Lake J.P., Ziegler H.K., and Kapp J.A. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J. Immunol. 158 (1997) 3610-3618
104. Spahn T.W., Issazadah S., Salvin A.J., and Weiner H.L. Decreased severity of myelin oligodendrocyte glycoprotein peptide 33-35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR delta chain gene. Eur. J. Immunol. 29 (1999) 4060-4071
105. McMenamin C., McKersey M., Kuhnlein P., Hunig T., and Holt P.G. Gamma delta T cells down-regulate primary IgE responses in rats to inhaled soluble protein antigens. J. Immunol. 154 (1995) 4390-4394
106. Kweon M.N., et al. Lack of orally induced systemic unresponsiveness in IFN-gamma knockout mice. J. Immunol. 160 (1998) 1687-1693
107. Lee H.O., et al. Interferon gamma induction during oral tolerance reduces T-cell migration to sites of inflammation. Gastroenterology 119 (2000) 129-138
108. Turcanu V., Maleki S.J., and Lack G. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J. Clin. Invest. 111 (2003) 1065-1072
109. Garside P., Steel M., Liew F.Y., and Mowat A.M. CD4+ but not CD8+ T cells are required for the induction of oral tolerance. Int. Immunol. 7 (1995) 501-504
110. Barone K.S., Jain S.L., and Michael J.G. Effect of in vivo depletion of CD4+ and CD8+ cells on the induction and maintenance of oral tolerance. Cell. Immunol. 163 (1995) 19-29
111. Desvignes C., Bour H., Nicolas J.F., and Kaiserlian D. Lack of oral tolerance but oral priming for contact sensitivity to dinitrofluorobenzene in major histocompatibility complex class II-deficient mice and in CD4+ T cell-depleted mice. Eur. J. Immunol. 26 (1996) 1756-1761
112. Mattingly P.C., and Mowat A.G. Zinc sulphate in rheumatoid arthritis. Ann. Rheum. Dis. 41 (1982) 456-457
113. Lider O., et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J. Clin. Invest. 83 (1989) 752-756
114. Miller A., al-Sabbagh A., Santos L.M., Das M.P., and Weiner H.L. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immunol. 151 (1993) 7307-7315
115. von Herrath M.G., Dyrberg T., and Oldstone M.B. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J. Clin. Invest. 98 (1996) 1324-1331
116. den Haan J.M., and Bevan M.J. Antigen presentation to CD8+ T cells: cross-priming in infectious diseases. Curr. Opin. Immunol. 13 (2001) 437-441
117. Maecker H.T., et al. Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens. J. Immunol. 166 (2001) 7268-7275
118. Wang R., Ramaswamy S., Hu D., and Cantor H. Definition of a novel binding site on CD8 cells for a conserved region of the MHC class Ib molecule Qa-1 that regulates IFN-gamma expression. Eur. J. Immunol. 31 (2001) 87-93
119. Hu D., et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat. Immunol. 5 (2004) 516-523
120. Vistica B.P., et al. CD8 T-cells are not essential for the induction of "low-dose" oral tolerance. Clin. Immunol. Immunopathol. 78 (1996) 196-202
121. Grdic D., Hornquist E., Kjerrulf M., and Lycke N.Y. Lack of local suppression in orally tolerant CD8-deficient mice reveals a critical regulatory role of CD8+ T cells in the normal gut mucosa. J. Immunol. 160 (1998) 754-762
122. Gonnella P.A., Waldner H.P., and Weiner H.L. B cell-deficient (mu MT) mice have alterations in the cytokine microenvironment of the gut-associated lymphoid tissue (GALT) and a defect in the low dose mechanism of oral tolerance. J. Immunol. 166 (2001) 4456-4464
123. Chen Y., Inobe J., and Weiner H.L. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. J. Immunol. 155 (1995) 910-916
124. Trop S., et al. Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Hepatology 29 (1999) 746-755
125. Samsonov D., Trop S., Alper R., Diment J., and Ilan Y. Enhancement of immune tolerance via induction of NK1.1 positive liver-associated-lymphocytes under immunosuppressive conditions. J. Hepatol. 32 (2000) 812-820
126. Margenthaler J.A., Landeros K., Kataoka M., and Flye M.W. CD1-dependent natural killer (NK1.1(+)) T cells are required for oral and portal venous tolerance induction. J. Surg. Res. 104 (2002) 29-35
127. Ishimitsu R., Yajima T., Nishimura H., Kawauchi H., and Yoshikai Y. NKT cells are dispensable in the induction of oral tolerance but are indispensable in the abrogation of oral tolerance by prostaglandin E. Eur. J. Immunol. 33 (2003) 183-193
128. Fukaura H., et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. 98 (1996) 70-77
129. Weiner H.L., et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259 (1993) 1321-1324
130. Teitelbaum D., Arnon R., and Sela M. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3842-3847
131. Weiner H.L. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3333-3335
132. Barnett M.L., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 41 (1998) 290-297
133. Choy E.H., et al. Control of rheumatoid arthritis by oral tolerance. Arthritis. Rheum. 44 (2001) 1993-1997
134. Yoshino S. Downregulation of silicone-induced chronic arthritis by gastric administration of type II collagen. Immunopharmacology 31 (1995) 103-108
135. Trentham D.E., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993) 1727-1730
136. Postlethwaite A.E. Can we induce tolerance in rheumatoid arthritis?. Curr. Rheumatol. Rep. 3 (2001) 64-69
137. Barnett M.L., Combitchi D., and Trentham D.E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 39 (1996) 623-628
138. Myers L.K., et al. Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum. 44 (2001) 1775-1781
139. Chaillous L., et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356 (2000) 545-549
140. Monetini L., et al. Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin. Diabetologia 47 (2004) 1795-1802
141. Kupila A., et al. Intranasally administered insulin intended for prevention of type 1 diabetes-a safety study in healthy adults. Diabetes Metab. Res. Rev. 19 (2003) 415-420
142. Ergun-Longmire B., et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann. N. Y. Acad. Sci. 1029 (2004) 260-277
143. Skyler J.S., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 28 (2005) 1068-1076
144. Nussenblatt R.B., et al. Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann. N. Y. Acad. Sci. 778 (1996) 325-337
145. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 2673-2677
146. Anolik J.H., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48 (2003) 455-459
147. Albert D., et al. Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann. Rheum. Dis. (2008)
148. Eisenberg R. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr. Metab. Immune. Disord. Drug Targets 6 (2006) 345-350
149. Sabahi R., and Anolik J.H. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66 (2006) 1933-1948
150. Thatayatikom A., and White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun. Rev. 5 (2006) 18-24
151. Looney R.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50 (2004) 2580-2589
152. Dorner T., et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8 (2006) R74
153. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator. Drugs R D 9, 197-202 (2008).
154. Carr R.I., Tilley D., Forsyth S., Etheridge P., and Sadi D. Failure of oral tolerance in (NZB X NZW)F1 mice is antigen specific and appears to parallel antibody patterns in human systemic lupus erythematosus (SLE). Clin. Immunol. Immunopathol. 42 (1987) 298-310
155. Akadegawa K., et al. Breakdown of mucosal immunity in the gut and resultant systemic sensitization by oral antigens in a murine model for systemic lupus erythematosus. J. Immunol. 174 (2005) 5499-5506
156. Wu H.Y., Monsonego A., and Weiner H.L. The mechanism of nasal tolerance in lupus prone mice is T-cell anergy induced by immature B cells that lack B7 expression. J. Autoimmun. 26 (2006) 116-126
157. Houssiau F.A., et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4 (1995) 393-395
158. Park Y.B., et al. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 16 (1998) 283-288
159. Llorente L., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43 (2000) 1790-1800